Please wait a minute...
 Home  About the Journal Editorial Board Aims & Scope Peer Review Policy Subscription Contact us
 
Early Edition  //  Current Issue  //  Open Special Issues  //  Archives  //  Most Read  //  Most Downloaded  //  Most Cited
Aging and disease    2016, Vol. 7 Issue (3) : 237-245     DOI: 10.14336/AD.2015.1030
Original Article |
Higher Plasma LDL-Cholesterol is Associated with Preserved Executive and Fine Motor Functions in Parkinson’s Disease
Sterling Nicholas W.1, Lichtenstein Maya1, Lee Eun-Young1, Lewis Mechelle M.1,2, Evans Alicia1, Eslinger Paul J.1,3,4, Du Guangwei1, Gao Xiang7, Chen Honglei8, Kong Lan3, Huang Xuemei1,2,4,5,6,*
1Departments of Neurology, Pennsylvania State University-Milton S. Hershey Medical Center, Hershey PA 17033, USA.
3Pharmacology, Pennsylvania State University-Milton S. Hershey Medical Center, Hershey PA 17033, USA.
2Public Health Sciences, Pennsylvania State University-Milton S. Hershey Medical Center, Hershey PA 17033, USA.
4Radiology, Pennsylvania State University-Milton S. Hershey Medical Center, Hershey PA 17033, USA.
5Neurosurgery, Pennsylvania State University-Milton S. Hershey Medical Center, Hershey PA 17033, USA.
6Kinesiology, Pennsylvania State University-Milton S. Hershey Medical Center, Hershey PA 17033, USA.
7Department of Nutritional Sciences, the Pennsylvania State University, University Park, PA 16802, USA.
8Epidemiology Branch/Aging & Neuroepidemiology Group, National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709, USA
Download: PDF(817 KB)   HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks    
Abstract  

Plasma low density lipoprotein (LDL) cholesterol has been associated both with risk of Parkinson’s disease (PD) and with age-related changes in cognitive function. This prospective study examined the relationship between baseline plasma LDL-cholesterol and cognitive changes in PD and matched Controls. Fasting plasma LDL-cholesterol levels were obtained at baseline from 64 non-demented PD subjects (62.7 ± 7.9 y) and 64 Controls (61.3 ± 6.8 y). Subjects underwent comprehensive neuropsychological testing at baseline, 18-, and 36-months. Linear mixed-effects modeling was used to assess the relationships between baseline LDL-cholesterol levels and longitudinal cognitive changes. At baseline, PD patients had lower scores of fine motor (p<0.0001), executive set shifting (p=0.018), and mental processing speed (p=0.049) compared to Controls. Longitudinally, Controls demonstrated improved fine motor and memory test scores (p=0.044, and p=0.003), whereas PD patients demonstrated significantly accelerated loss in fine motor skill (p=0.002) compared to Controls. Within the PD group, however, higher LDL-cholesterol levels were associated with improved executive set shifting (β=0.003, p<0.001) and fine motor scores (β=0.002, p=0.030) over time. These associations were absent in Controls (p>0.7). The cholesterol - executive set shifting association differed significantly between PDs and Controls (interaction p=0.005), whereas the cholesterol - fine motor association difference did not reach significance (interaction, p=0.104). In summary, higher plasma LDL-cholesterol levels were associated with better executive function and fine motor performance over time in PD, both of which may reflect an effect on nigrostriatal mediation. Confirmation of these results and elucidation of involved mechanisms are warranted, and might lead to feasible therapeutic strategies.

Keywords Parkinson’s disease      cholesterol      low density lipoprotein cholesterol (LDL-cholesterol)      cognition      neuroprotection      executive function     
Corresponding Authors: Huang Xuemei   
About author:

These authors equally contribute this work

Issue Date: 09 January 2016
Service
E-mail this article
E-mail Alert
RSS
Articles by authors
Sterling Nicholas W.
Lichtenstein Maya
Lee Eun-Young
Lewis Mechelle M.
Evans Alicia
Eslinger Paul J.
Du Guangwei
Gao Xiang
Chen Honglei
Kong Lan
Huang Xuemei
Cite this article:   
Sterling Nicholas W.,Lichtenstein Maya,Lee Eun-Young, et al. Higher Plasma LDL-Cholesterol is Associated with Preserved Executive and Fine Motor Functions in Parkinson’s Disease[J]. Aging and disease, 2016, 7(3): 237-245.
URL:  
http://www.aginganddisease.org/EN/10.14336/AD.2015.1030     OR     http://www.aginganddisease.org/EN/Y2016/V7/I3/237
PD, n=64Control, n=64P-values
n, Female : n, Male26 : 3832 : 320.374
Statin Use (No : Yes)46 : 1849 : 150.686
Smoker (No : Yes)48 : 1649 : 151.000
Age (years)62.7 ± 7.961.3 ± 6.80.268
Education (years)15.6 ± 2.816.9 ± 2.60.008
LDL-cholesterol (mg/dL)127.3 ± 33.0126.5 ± 41.30.616
MMSE29.3 ± 1.029.5 ± 0.90.698
Hamilton Depression Scale7.7 ± 4.84.0 ± 2.6<0.0001
LEDD (mg)709 ± 481NA-
Disease duration (years)4.4 ± 4.4NA-
Hoehn & Yahr Score1.7 ± 0.7NA
Table 1  Demographics of study subjects at baseline (averages presented as mean ± SD)
Cognitive DomainIndividual Tests
Fine motor speedGrooved Pegboard Test
MemoryBrief Visuospatial Memory Test-Revised (BVMT-R)
Hopkins Verbal Learning Test-Revised (HVLT-R)
Executive function: Spontaneous flexibilityDKEFS Design Fluency Test (DesFlu)
Verbal Fluency Test (VerbFlu)
Executive function:
Set-shifting
CWInt-Switch and CWInt-Inhibition subtests, including error scores
Attention//Working memoryDigit Span
Spatial Span
Letter-Number Sequencing Test
Processing speedCWInt color
Symbol search
LanguageBoston Naming Test (BNT)
CWInt-Word subtest
Spatial cognitionBenton’s Judgment of Line Orientation (JoLO)
Table 2  Individual cognitive tests comprising cognitive domains
PDControlP-values
Baseline Visit
Fine Motor Speed-2.03 ± 1.11-0.46 ± 1.08<0.001
Memory-0.59 ± 0.91-0.45 ± 0.920.403
Executive Function: SF0.11 ± 0.780.43 ± 0.700.090
Executive Function: SS-0.01 ± 0.940.44 ± 0.470.018
Attention0.29 ± 0.6610.37 ± 0.530.803
Processing Speed0.08 ± 0.570.29 ± 0.320.049
Language0.29 ± 0.800.51 ± 0.490.246
Spatial Cognition-0.27 ± 0.93-0.19 ± 0.770.787
18-Months Visit
Fine Motor Speed-2.03 ± 1.06-0.31 ± 0.98<0.001
Memory-0.60 ± 0.81-0.24 ± 0.800.067
Executive Function: SF0.00 ± 0.870.27 ± 0.730.095
Executive Function: SS0.01 ± 0.880.46 ± 0.410.008
Attention0.19 ± 0.750.36 ± 0.550.456
Processing Speed-0.02 ± 0.590.23 ± 0.310.022
Language0.19 ± 0.760.54 ± 0.480.015
Spatial Cognition-0.18 ± 0.91-0.15 ± 1.000.610
36-Months Visit
Fine Motor Speed-2.09 ± 1.09-0.19 ± 0.97<0.001
Memory-0.45 ± 0.92-0.05 ± 0.740.098
Executive Function: SF-0.08 ± 0.730.37 ± 0.760.022
Executive Function: SS0.21 ± 0.740.52 ± 0.470.059
Attention0.33 ± 0.590.34 ± 0.560.949
Processing Speed0.08 ± 0.560.21 ± 0.380.300
Language0.32 ± 0.860.64 ± 0.440.053
Spatial Cognition-0.11 ± 0.59-0.13 ± 0.830.952
Table 3  Association of baseline LDL-cholesterol levels with change in cognitive function over time (using baseline, 18-month, and 36-month scores)
Figure 1.  Annual rates of changes in cognitive function over time associated with baseline plasma LDL-cholesterol levels

Annual rates of change estimated using linear regression of baseline, 18-month, and 36-month cognitive z-scores.

PDControlsGroup Difference
EstimateP-ValueEstimateP-ValueEstimateP-Value
Fine motor speed0.0020.0300.0000.8010.0020.104
Memory0.0010.2890.0010.3940.0010.726
Executive function: SF0.0000.7410.0000.4820.0000.900
Executive function: SS0.003<0.001*0.0000.9050.0030.005*
Attention0.0010.5000.0010.035-0.0010.526
Processing speed0.0000.7420.0000.8110.0000.889
Language0.0010.2400.0000.9670.0010.348
Spatial cognition0.0010.5630.0000.8750.0010.705
Table 4  Association of baseline LDL-cholesterol levels with change in cognitive function over time (using baseline, 18-month, and 36-month scores)
[1] Rodriguez-Ferreiro J, Cuetos F, Herrera E, Menendez M, Ribacoba R (2010). Cognitive impairment in Parkinson’s disease without dementia. Mov. Disord., 25: 2136-2141
[2] Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG (2008). The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov. Disord., 23: 837-844
[3] Kivipelto M, Helkala EL, Hanninen T, Laakso MP, Hallikainen M, Alhainen K, et al. (2001). Midlife vascular risk factors and late-life mild cognitive impairment: A population-based study. Neurology, 56: 1683-1689
[4] Notkola IL, Sulkava R, Pekkanen J, Erkinjuntti T, Ehnholm C, Kivinen P, et al. (1998). Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer’s disease. Neuroepidemiology, 17: 14-20
[5] Solomon A, Kareholt I, Ngandu T, Winblad B, Nissinen A, Tuomilehto J, et al. (2007). Serum cholesterol changes after midlife and late-life cognition: twenty-one-year follow-up study. Neurology, 68: 751-756
[6] Mielke MM, Zandi PP, Sjogren M, Gustafson D, Ostling S, Steen B, et al. (2005). High total cholesterol levels in late life associated with a reduced risk of dementia. Neurology, 64: 1689-1695
[7] West R, Beeri MS, Schmeidler J, Hannigan CM, Angelo G, Grossman HT, et al. (2008). Better memory functioning associated with higher total and low-density lipoprotein cholesterol levels in very elderly subjects without the apolipoprotein e4 allele. Am. J. Geriatr. Psychiatry, 16: 781-785
[8] Huang X, Chen H, Miller WC, Mailman RB, Woodard JL, Chen PC, et al. (2007). Lower low-density lipoprotein cholesterol levels are associated with Parkinson’s disease. Mov. Disord., 22: 377-381
[9] Scigliano G, Musicco M, Soliveri P, Piccolo I, Ronchetti G, Girotti F (2006). Reduced risk factors for vascular disorders in Parkinson disease patients: a case-control study. Stroke, 37: 1184-1188
[10] Miyake Y, Tanaka K, Fukushima W, Sasaki S, Kiyohara C, Tsuboi Y, et al. (2010). Case-control study of risk of Parkinson’s disease in relation to hypertension, hypercholesterolemia, and diabetes in Japan. J Neurol Sci, 293: 82-86
[11] Huang X, Abbott RD, Petrovitch H, Mailman RB, Ross GW (2008). Low LDL cholesterol and increased risk of Parkinson’s disease: prospective results from Honolulu-Asia Aging Study. Mov. Disord., 23: 1013-1018
[12] de Lau LM, Koudstaal PJ, Hofman A, Breteler MM (2006). Serum cholesterol levels and the risk of Parkinson’s disease. Am J Epidemiol, 164: 998-1002
[13] Simon KC, Chen H, Schwarzschild M, Ascherio A (2007). Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease. Neurology, 69: 1688-1695
[14] Huang X, Alonso A, Guo X, Umbach DM, Lichtenstein ML, Ballantyne CM, et al. (2015). Statins, plasma cholesterol, and risk of Parkinson’s disease: A prospective study. Mov. Disord.
[15] Hu G, Antikainen R, Jousilahti P, Kivipelto M, Tuomilehto J (2008). Total cholesterol and the risk of Parkinson disease. Neurology, 70: 1972-1979
[16] Huang X, Auinger P, Eberly S, Oakes D, Schwarzschild M, Ascherio A, et al. (2011). Serum cholesterol and the progression of Parkinson’s disease: results from DATATOP. PLoS ONE, 6: e22854
[17] Postuma RB, Iranzo A, Hogl B, Arnulf I, Ferini-Strambi L, Manni R, et al. (2015). Risk factors for neurodegeneration in idiopathic rapid eye movement sleep behavior disorder: A multicenter study. Ann Neurol, 77: 830-839
[18] Ho D, Imai K, King G, Stuart E (2006). Matchit: nonparametric preprocessing for parametric casual inference. R package version: 2.2-11
[19] Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ (1992). What features improve the accuracy of clinical diagnosis in Parkinson’s disease: a clinicopathologic study. Neurology, 42: 1142-1146
[20] Hobson P, Meara J (1999). The detection of dementia and cognitive impairment in a community population of elderly people with Parkinson’s disease by use of the CAMCOG neuropsychological test. Age and ageing, 28: 39-43
[21] Allain CC, Poon LS, Chan CS, Richmond W, Fu PC (1974). Enzymatic determination of total serum cholesterol. Clin Chem, 20: 470-475
[22] Lucassen EB, Sterling NW, Lee EY, Chen H, Lewis MM, Kong L, et al. (2014). History of smoking and olfaction in Parkinson’s disease. Mov. Disord., 29: 1069-1074
[23] Hamilton M (1960). A rating scale for depression. J Neurol Neurosurg Psychiatry, 23: 56-62
[24] Langston JW, Widner H, Goetz CG, Brooks D, Fahn S, Freeman T, et al. (1992). Core assessment program for intracerebral transplantations (CAPIT). Mov. Disord., 7: 2-13
[25] Lafayette Instrument (2002). Grooved Pegboard Test Manual.
[26] Benedict RH (1997) Brief visuospatial memory test--revised: professional manual, PAR
[27] Brandt J, Benedict R (2001) Hopkins Verbal Learning Test—revised. Professional manual, Psychological Assessment Resources, Inc, Lutz, FL
[28] Homack S, Lee D, Riccio CA (2005). Test review: Delis-Kaplan executive function system. J. Clin. Exp. Neuropsychol., 27: 599-609
[29] Wechsler D (1997) Wechsler Memory Scale - III, Psychological Corporation, San Antonio TX
[30] Wechsler D (2008) Wechsler adult intelligence scale-Fourth Edition (WAIS-IV)
[31] Kaplan E, Goodglass H, Weintraub S (1983) Boston Naming Test, Lee & Febiger, Philadelphia
[32] Benton AL, Hamsher K, Varney NR, Spreen O (1983) Judgment of line orientation, Oxford University Press New York
[33] Miller RGJ (2011) Simultaneous Statistical Inference, Springer New York
[34] Wilson BA, Watson PC, Baddeley AD, Emslie H, Evans JJ (2000). Improvement or simply practice? The effects of twenty repeated assessments on people with and without brain injury. J. Int. Neuropsychol. Soc., 6: 469-479
[35] McCaffrey RJ, Ortega A, Haase RF (1993). Effects of repeated neuropsychological assessments. Arch. Clin. Neuropsychol., 8: 519-524
[36] Gover M, Duff K, Tremont G, Westervelt H (2014). Practice Effects in Mild Cognitive Impairment and Alzheimer’s Disease: Gaining Additional Information within a Single Testing Session. Arch. Clin. Neuropsychol., 29: 533
[37] Litvan I, Goldman JG, Troster AI, Schmand BA, Weintraub D, Petersen RC, et al. (2012). Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: Movement Disorder Society Task Force guidelines. Mov. Disord., 27: 349-356
[38] Bohnen NI, Kuwabara H, Constantine GM, Mathis CA, Moore RY (2007). Grooved pegboard test as a biomarker of nigrostriatal denervation in Parkinson’s disease. Neurosci Lett, 424: 185-189
[39] Monchi O, Petrides M, Doyon J, Postuma RB, Worsley K, Dagher A (2004). Neural bases of set-shifting deficits in Parkinson’s disease. J Neurosci, 24: 702-710
[40] Du G, Lewis MM, Shaffer ML, Chen H, Yang QX, Mailman RB, et al. (2012). Serum cholesterol and nigrostriatal R2* values in Parkinson’s disease. PLoS ONE, 7: e35397
[41] Bohnen NI, Muller ML, Kuwabara H, Cham R, Constantine GM, Studenski SA (2009). Age-associated striatal dopaminergic denervation and falls in community-dwelling subjects. J. Rehabil. Res. Dev., 46: 1045-1052
[42] Mauch DH, Nagler K, Schumacher S, Goritz C, Muller EC, Otto A, et al. (2001). CNS synaptogenesis promoted by glia-derived cholesterol. Science, 294: 1354-1357
[43] Goritz C, Mauch DH, Nagler K, Pfrieger FW (2002). Role of glia-derived cholesterol in synaptogenesis: new revelations in the synapse-glia affair. J Physiol Paris, 96: 257-263
[44] Vance JE, Karten B, Hayashi H (2006). Lipid dynamics in neurons. Biochem Soc Trans, 34: 399-403
[45] Orth M, Bellosta S (2012). Cholesterol: its regulation and role in central nervous system disorders. Cholesterol, 2012: 292598
[46] Cheng D, Jenner AM, Shui G, Cheong WF, Mitchell TW, Nealon JR, et al. (2011). Lipid pathway alterations in Parkinson’s disease primary visual cortex. PLoS ONE, 6: e17299
[47] Bjorkhem I, Lovgren-Sandblom A, Leoni V, Meaney S, Brodin L, Salveson L, et al. (2013). Oxysterols and Parkinson’s disease: evidence that levels of 24S-hydroxycholesterol in cerebrospinal fluid correlates with the duration of the disease. Neurosci Lett, 555: 102-105
[48] Lee CY, Seet RC, Huang SH, Long LH, Halliwell B (2009). Different patterns of oxidized lipid products in plasma and urine of dengue fever, stroke, and Parkinson’s disease patients: cautions in the use of biomarkers of oxidative stress. Antioxid Redox Signal, 11: 407-420
[49] Koob AO, Ubhi K, Paulsson JF, Kelly J, Rockenstein E, Mante M, et al. (2010). Lovastatin ameliorates alpha-synuclein accumulation and oxidation in transgenic mouse models of alpha-synucleinopathies. Exp Neurol, 221: 267-274
[50] Yan J, Xu Y, Zhu C, Zhang L, Wu A, Yang Y, et al. (2011). Simvastatin prevents dopaminergic neurodegeneration in experimental parkinsonian models: the association with anti-inflammatory responses. PLoS ONE, 6: e20945
[1] Yong-Fei Zhao, Qiong Zhang, Jian-Feng Zhang, Zhi-Yin Lou, Hen-Bing Zu, Zi-Gao Wang, Wei-Cheng Zeng, Kai Yao, Bao-Guo Xiao. The Synergy of Aging and LPS Exposure in a Mouse Model of Parkinson’s Disease[J]. Aging and disease, 2018, 9(5): 785-797.
[2] Diano F. Marrone, Elham Satvat, Anuj Patel. Age-related Deficits in Recognition Memory are Protocol-Dependent[J]. Aging and disease, 2018, 9(5): 798-807.
[3] Fan Liu, Jianfei Lu, Anatol Manaenko, Junjia Tang, Qin Hu. Mitochondria in Ischemic Stroke: New Insight and Implications[J]. Aging and disease, 2018, 9(5): 924-937.
[4] De Lazzari Federica, Bubacco Luigi, Whitworth Alexander J, Bisaglia Marco. Superoxide Radical Dismutation as New Therapeutic Strategy in Parkinson’s Disease[J]. Aging and disease, 2018, 9(4): 716-728.
[5] Vinagre Carmen G, Freitas Fatima R, de Mesquita Carlos H, Vinagre Juliana C, Mariani Ana Carolina, Kalil-Filho Roberto, Maranhão Raul C. Removal of Chylomicron Remnants from the Bloodstream is Delayed in Aged Subjects[J]. Aging and disease, 2018, 9(4): 748-754.
[6] Zhang Li, Hao Junwei, Zheng Yan, Su Ruijun, Liao Yajin, Gong Xiaoli, Liu Limin, Wang Xiaomin. Fucoidan Protects Dopaminergic Neurons by Enhancing the Mitochondrial Function in a Rotenone-induced Rat Model of Parkinson’s Disease[J]. Aging and disease, 2018, 9(4): 590-604.
[7] Morroni Fabiana, Sita Giulia, Graziosi Agnese, Turrini Eleonora, Fimognari Carmela, Tarozzi Andrea, Hrelia Patrizia. Neuroprotective Effect of Caffeic Acid Phenethyl Ester in A Mouse Model of Alzheimer’s Disease Involves Nrf2/HO-1 Pathway[J]. Aging and disease, 2018, 9(4): 605-622.
[8] Chen Yali, Yin Mengmei, Cao Xuejin, Hu Gang, Xiao Ming. Pro- and Anti-inflammatory Effects of High Cholesterol Diet on Aged Brain[J]. Aging and disease, 2018, 9(3): 374-390.
[9] Yan Tao, Venkat Poornima, Chopp Michael, Zacharek Alex, Yu Peng, Ning Ruizhuo, Qiao Xiaoxi, Kelley Mark R., Chen Jieli. APX3330 Promotes Neurorestorative Effects after Stroke in Type One Diabetic Rats[J]. Aging and disease, 2018, 9(3): 453-466.
[10] Zhang Zheng, Zhang Linlei, Ding Yuchuan, Han Zhao, Ji Xunming. Effects of Therapeutic Hypothermia Combined with Other Neuroprotective Strategies on Ischemic Stroke: Review of Evidence[J]. Aging and disease, 2018, 9(3): 507-522.
[11] Deng Qi-Wen, Li Shuo, Wang Huan, Lei Leix, Zhang Han-Qing, Gu Zheng-Tian, Xing Fang-Lan, Yan Fu-Ling. The Short-term Prognostic Value of the Triglyceride-to-high-density Lipoprotein Cholesterol Ratio in Acute Ischemic Stroke[J]. Aging and disease, 2018, 9(3): 498-506.
[12] Perez-Roca Laia, Adame-Castillo Cristina, Campdelacreu Jaume, Ispierto Lourdes, Vilas Dolores, Rene Ramon, Alvarez Ramiro, Gascon-Bayarri Jordi, Serrano-Munoz Maria A., Ariza Aurelio, Beyer Katrin. Glucocerebrosidase mRNA is Diminished in Brain of Lewy Body Diseases and Changes with Disease Progression in Blood[J]. Aging and disease, 2018, 9(2): 208-219.
[13] Zhang Meng, Deng Yong-Ning, Zhang Jing-Yi, Liu Jie, Li Yan-Bo, Su Hua, Qu Qiu-Min. SIRT3 Protects Rotenone-induced Injury in SH-SY5Y Cells by Promoting Autophagy through the LKB1-AMPK-mTOR Pathway[J]. Aging and disease, 2018, 9(2): 273-286.
[14] Sun Qian, Wang Tian, Jiang Tian-Fang, Huang Pei, Wang Ying, Xiao Qin, Liu Jun, Chen Sheng-Di. Clinical Profile of Chinese Long-Term Parkinson’s Disease Survivors With 10 Years of Disease Duration and Beyond[J]. Aging and disease, 2018, 9(1): 8-16.
[15] Wang Ningqun, Ji Shaozhen, Zhang Hao, Mei Shanshan, Qiao Lumin, Jin Xianglan. Herba Cistanches: Anti-aging[J]. Aging and disease, 2017, 8(6): 740-759.
Viewed
Full text


Abstract

Cited

  Shared   
Copyright © 2014 Aging and Disease, All Rights Reserved.
Address: Aging and Disease Editorial Office 3400 Camp Bowie Boulevard Fort Worth, TX76106 USA
Fax: (817) 735-0408 E-mail: editorial@aginganddisease.org
Powered by Beijing Magtech Co. Ltd